Dihydroartemisinin-Piperaquine is a fixed-dose artemisinin-based combination therapy (ACT) used to treat uncomplicated Plasmodium falciparum malaria. It combines:

Dihydroartemisinin (DHA): a fast-acting antimalarial that rapidly reduces the parasite load in the blood.

Piperaquine: a long-acting partner drug that prevents recurrence by eliminating remaining parasites.

This combination is typically administered orally over a 3-day course and is well-tolerated in both adults and children. Its long post-treatment prophylactic effect also helps reduce the risk of reinfection in endemic areas.